立命館大学 研究者学術情報データベース
English>>
TOPページ
カシワ ムネノブ
柏 宗伸
KASHIWA MUNENOBU
所属
総合科学技術研究機構
職名
准教授
論文
1.
2024/09/21
Comparative Cost-Effectiveness of Atezolizumab Versus Durvalumab as First-Line Combination Treatment with Chemotherapy for Patients with Extensive-Disease Small-Cell Lung Cancer in Japan │ Clinical Drug Investigation │
2.
2024/08/22
Comparative Cost-Effectiveness of Gemcitabine and Cisplatin in Combination with S-1, Durvalumab, or Pembrolizumab as First-Line Triple Treatment for Advanced Biliary Tract Cancer │ Journal of Gastrointestinal Cancer │
3.
2023/06/01
Comparative cost-effectiveness of nivolumab first-line and second-line therapy for advanced esophageal cancer in Japan. │ The European journal of health economics : HEPAC : health economics in prevention and care │
4.
2023/04/20
Model-based cost-utility analysis of gemcitabine, cisplatin, and S-1 as triple therapy for advanced biliary tract cancer │ International Journal of Clinical Pharmacy │
5.
2022
Difference in Cost-Effectiveness between First-Line and Third-Line or Later Nivolumab Therapy in Patients with HER2-Negative, Unresectable, Advanced or Recurrent Gastric or Gastro-Esophageal Junction Cancer in Japan. │ Biological & pharmaceutical bulletin │ 45 (7),895-903頁
6.
2021/10/01
Cost-effectiveness of preemptive skin treatment to prevent skin-toxicity caused by panitumumab in third-line therapy for KRAS wild type metastatic colorectal cancer in Japan. │ Journal of pharmaceutical health care and sciences │ 7 (1),35-35頁
7.
2020/07
Comparative Cost-effectiveness of Aflibercept and Ramucirumab in Combination with Irinotecan and Fluorouracil-based Therapy for the Second-line Treatment of Metastatic Colorectal Cancer in Japan. │ Clinical therapeutics │ 42 (7),1361-1375頁
8.
2020/07
Comparative Cost-utility Analysis of Regorafenib and Trifluridine/Tipiracil in The Treatment of Metastatic Colorectal Cancer in Japan. │ Clinical therapeutics │ 42 (7),1376-1387頁
9.
2019/07/01
Cost-utility analysis of palonosetron in the antiemetic regimen for cisplatin-containing highly emetogenic chemotherapy in Japan. │ BMC health services research │ 19 (1),438-438頁
10.
2019/05
Comparative Cost-utility Analysis Between Aprepitant- and Fosaprepitant-containing Regimens To Prevent Chemotherapy-induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy in Japan. │ Clinical therapeutics │ 41 (5),929-942頁